title: Primary cutaneous cryptococcosis during infliximab therapy.
authors.affiliation: Department of Dermatology, Apollonia University, Iasi, Romania.
authors.forename: Anca
authors.initials: A
authors.lastname: Chiriac
authors.affiliation: Laboratory of Antimicrobial Chemotherapy, "Ion Ionescu de la Brad" University, Iasi, Romania.
authors.forename: Mihai
authors.initials: M
authors.lastname: Mares
authors.affiliation: Department of Pathology, Saint Mary Emergency Hospital for Children, Iasi, Romania.
authors.forename: Doina
authors.initials: D
authors.lastname: Mihaila
authors.affiliation: Department of Dermatology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
authors.forename: Caius
authors.initials: C
authors.lastname: Solovan
authors.affiliation: Department of Histology, University of Medicine and Pharmacy of Tirgu Mures, Romania.
authors.forename: Cosmin
authors.identifier: http://orcid.org/0000-0003-0223-4292
authors.initials: C
authors.lastname: Moldovan
authors.affiliation: Department of Pathology, University of Medicine and Pharmacy of Tirgu Mures, Romania.
authors.forename: Simona
authors.initials: S
authors.lastname: Stolnicu
authors.affiliation: Department of Medical Microbiology & Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
authors.forename: Ferry
authors.initials: F
authors.lastname: Hagen
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001706:Biopsy; D003453:Cryptococcosis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D003455:Cryptococcus neoformans / Q000276:immunology / Q000302:isolation & purification*; D003881:Dermatomycoses / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab / Q000009:adverse effects*; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D018501:Antirheumatic Agents; D015725:Fluconazole; D000069285:Infliximab